source
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 failEvommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
- Biopharma looks beyond China to five alternative overseas markets amid rising geopolitical tensionsGeopolitical tensions between the United States and China are prompting biopharma companies to look beyond the Chinese market for growth. China remains the leading destination, with licensing deal…